Merck Settles Fosamax Jaw-Injury Claims For $28M

Law360, New York (December 9, 2013, 6:47 PM EST) -- Resolving long-running multidistrict litigation in New York, Merck & Co. Inc. agreed Monday to pay $27.7 million to settle hundreds of lawsuits claiming its bone drug Fosamax caused a condition known as osteonecrosis of the jaw.

The agreement includes the claims of about 1,200 plaintiffs in federal and state court, Merck said. It comes after U.S. District Judge John Keenan ordered the parties to transfer 200 cases per month out of the multidistrict litigation and into their home courts, though no such transfer has yet occurred....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.